Please assess the completion status of the following clinical trial:

Trial Title: AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must have chemotherapy-resistant acute leukemia (primary refractory or relapsed and refractory AML, ALL, undifferentiated, bi-lineage or mixed lineage leukemia)~* Participant must have a well HLA matched related, mismatched related or unrelated marrow donor with whom the patient is allele matched at at least 7 of 8 HLA loci or a single unrelated cord blood unit matched at at least 4 of 6 HLA loci with minimal dose of 4x10(7)NC/Kg~Exclusion Criteria:~* Prior allogeneic or autologous hematopoietic stem cell transplantation~* Prior exposure to AMD3100~* Active central nervous system leukemia~* Uncontrolled viral, bacterial, fungal, protozoal infection~* HIV infection~* Does not meet standard organ function for transplant

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 22 Years
- Healthy Volunteers: f

Study Arms:
- bone marrow transplant (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).